Six1 gene promoter's methylation in gastric cancer and its value for evaluating the disease condition and prognosis

Fan-jing KONG,Hong-gang YU,Zhong-yin ZHOU,Ji-wang CAO,Ming-kai Chen
DOI: https://doi.org/10.3969/j.issn.1006-3110.2017.04.007
2017-01-01
Abstract:Objective To detect Six1 gene promoter's hypomethylation in patients with gastric cancer and study its clinical value in assessing the disease condition and prognosis.Methods Methylation specific PCR (MSP) was used to detect the methylation of Six1 gene promoter in gastric cancer tissue (gastric cancer group) and in gastric tissue of gastritis patients (the control group),and the detection results were compared between the two groups.The relationship between clinicopathological factors and Six1 gene promoter's methylation was analyzed.The differences of surgical result,3-year mortality and progression-free survival (PFS) between patients with Six1 gene promoter methylation and unmethylation in the gastric cancer group were compared.Results The methylation rate of Six1 gene promoter in the tumor tissues of the gastric cancer group was significantly lower than that in the gastric tissues of the control group (24.0% vs.95.0%,P<0.05).The prevalence of Six1 gene promoter's methylation in the gastric cancer group differred significantly in tumors with different Lauren's typing,histology differentiation,maximum tumor diameters,lymph node metastasis,distant metastasis and TNM staging (all P<0.05).The D2 radical operation rate,negative rate of surgical margin and PFS time in patients with Six1 gene promoter methylation were significantly higher than those in patients without Six1 gene promoter methylation (100.0% vs.57.9%,100.0% vs.47.4%,(23.6±3.5) months vs.(13.2±2.7) months,all P<0.05),while the 3-year mortality rate was significantly lower (P<0.05).Conclusions:Six1 gene promoter is hypomethylated in patients with gastric cancer,and it can serve as a tumor biomarker in disease condition and prognosis assessment.
What problem does this paper attempt to address?